{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T18:05:49Z","timestamp":1777917949131,"version":"3.51.4"},"reference-count":13,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2005,7,1]],"date-time":"2005-07-01T00:00:00Z","timestamp":1120176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tumori"],"published-print":{"date-parts":[[2005,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The management of patients with fluoropyrimidine-resistant advanced colorectal cancer remains investigational. Irinotecan and oxaliplatin have proved effective in first-line treatment in combination with 5-fluorouracil.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study design<\/jats:title>\n                    <jats:p>\n                      From February 1998 to September 2002, 34 patients with 5-fluorouracil-pretreated advanced colorectal cancer were enrolled in the study. Median age was 67 years (range, 32\u201376) and median performance status was 1. Twenty-one patients had multiple liver metastases. Other sites of disease included lungs, abdomen, pelvis, lymph nodes, bones and skin. They received six 28-day cycles of oxaliplatin (85 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      in a 2-h infusion on days 1 and 15) and irinotecan (80 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      in a 30-minute infusion on days 1,8 and 15 immediately following oxaliplatin).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirteen patients (39%) completed treatment. The most common grade III-IV toxicities were diarrhea (27%), anemia (6%), neutropenia (18%), alopecia (6%) and peripheral neuropathy (6%). Thirteen patients (39%) received G-CSF support, and there were 2 episodes of febrile neutropenia. There were no treatment-related deaths. Six patients (18%) had a partial remission and another 11 (33%), disease stabilization. There were no complete remissions. Median time to progression was 6.6 months (range, 0.8\u201320.1) and median survival 10.6 months (range, 0.8\u201352.9).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Irinotecan and oxaliplatin combination has modest activity as second line treatment of 5-fluorouracil-resistant advanced colorectal cancer. Further research is warranted for the development of more effective and less toxic regimens in this setting.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/030089160509100404","type":"journal-article","created":{"date-parts":[[2019,7,18]],"date-time":"2019-07-18T03:35:23Z","timestamp":1563420923000},"page":"309-313","source":"Crossref","is-referenced-by-count":7,"title":["Irinotecan and Oxaliplatin Combination, As Second-Line Treatment, In Fluoropyrimidine-Pretreated Advanced Colorectal Cancer. A Phase Ii Study by the Hellenic Cooperative Oncology Group (Hecog)"],"prefix":"10.1177","volume":"91","author":[{"given":"Eleni","family":"Timotheadou","sequence":"first","affiliation":[{"name":"Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pavlos","family":"Papakostas","sequence":"additional","affiliation":[{"name":"\u201cIppokration\u201d Hospital, Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitrios","family":"Tsavdaridis","sequence":"additional","affiliation":[{"name":"General Hospital IKA, Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Basdanis","sequence":"additional","affiliation":[{"name":"Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haralambos","family":"Kalofonos","sequence":"additional","affiliation":[{"name":"University of Patras School of Medicine, Patras, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerasimos","family":"Aravantinos","sequence":"additional","affiliation":[{"name":"\u201cAgii Anargiri\u201d Cancer Hospital, Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitrios","family":"Bafaloukos","sequence":"additional","affiliation":[{"name":"\u201cMetaxa\u201d Cancer Hospital, Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Fountzilas","sequence":"additional","affiliation":[{"name":"Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2005,7,1]]},"reference":[{"key":"bibr1-030089160509100404","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200009283431302"},{"key":"bibr2-030089160509100404","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02034-1"},{"key":"bibr3-030089160509100404","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.16.2938"},{"key":"bibr4-030089160509100404","first-page":"255","volume":"22","author":"Colucci G.","year":"2003","journal-title":"Proc ASCO"},{"key":"bibr5-030089160509100404","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.05.113"},{"key":"bibr6-030089160509100404","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.3.902"},{"key":"bibr7-030089160509100404","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6"},{"key":"bibr8-030089160509100404","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi047"},{"key":"bibr9-030089160509100404","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.11.069"},{"key":"bibr10-030089160509100404","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.09.046"},{"issue":"3","key":"bibr11-030089160509100404","volume":"15","author":"Seymour M.","year":"2004","journal-title":"Ann Oncol"},{"issue":"3","key":"bibr12-030089160509100404","first-page":"70","volume":"15","author":"Haller D.G.","year":"2004","journal-title":"Ann Oncol"},{"key":"bibr13-030089160509100404","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(02)00648-4"}],"container-title":["Tumori Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/030089160509100404","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/030089160509100404","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T18:26:53Z","timestamp":1777660013000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/030089160509100404"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,7]]},"references-count":13,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2005,7]]}},"alternative-id":["10.1177\/030089160509100404"],"URL":"https:\/\/doi.org\/10.1177\/030089160509100404","relation":{},"ISSN":["0300-8916","2038-2529"],"issn-type":[{"value":"0300-8916","type":"print"},{"value":"2038-2529","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,7]]}}}